Loading clinical trials...
Loading clinical trials...
The aim of this study is to determine the safety, tolerability and dose-limiting toxicities of KW-2478 and to determine the Maximum Tolerated Dose and recommended Phase II dose for patients with relap...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Kyowa Kirin Co., Ltd.
Collaborators
NCT07053436 · High Risk Newly Diagnosed Multiple Myeloma
NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04728893 · Hematologic Malignancies, Waldenstroms Macroglobulinaemia, and more
NCT07030517 · Multiple Myeloma
NCT02269592 · Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, and more
St Bartholomew's Hospital
London
UCLH
London
Christie Hospital
Manchester
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions